| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Lupus Anticoagulant Evaluation with Reflex (Client 6666)
Test Code38357
CPT Codes
85598 (x2), 85597, 85613, 85670<br>*** RESTRICTED USE *** This code is available to Client (6666) ONLY.
Includes
If the PTT-LA test is prolonged (>40 seconds), the Hexagonal Phase Confirm is performed at an additional charge.
If the Hexagonal Phase Confirm is positive or weakly positive, a Thrombin Clotting Time will be performed at an additional charge.
If the dRVVT screen is prolonged (>45 seconds), the dRVVT Confirm is performed at an additional charge.
If the dRVVT Confirm is positive, a dRVVT 1:1 Mix will be performed at an additional charge.
If the Hexagonal Phase Confirm is positive or weakly positive, a Thrombin Clotting Time will be performed at an additional charge.
If the dRVVT screen is prolonged (>45 seconds), the dRVVT Confirm is performed at an additional charge.
If the dRVVT Confirm is positive, a dRVVT 1:1 Mix will be performed at an additional charge.
Preferred Specimen
3 mL frozen platelet-poor plasma collected in a 3.2% sodium citrate (light blue-top) tube
Minimum Volume
2 mL
Instructions
Platelet-poor plasma: Centrifuge light blue-top tube for 15 minutes at approximately 1500 g within 60 minutes of collection. Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. Plasma must be free of platelets (<10,000/mcL). Freeze immediately and ship on dry ice.
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 90 days
Refrigerated: Unacceptable
Frozen: 90 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis • Received thawed
Methodology
Clot Detection
Setup Schedule
A.M. Sets up 6 days a week.
Report Available
Reports in 1 to 2 days.
Clinical Significance
Lupus Anticoagulants (LA) are members of a family of
antibodies with phospholipid-protein specificity. LA may be
defined as an immunoglobulin, IgG or IgM or a mixture of
both, that interferes with one or more of the in-vitro
phospholipid (PL) dependent tests of coagulation. These
antibodies are not associated with a hemorrhagic diathesis,
but rather have been linked to thrombotic events. In
addition to thrombosis, other clinical complications have
been associated with the presence of LA. These include
strokes, nonbacterial thrombotic endocarditis, livedo
reticularis and a variety of obstetrical complications such
as intrauterine fetal death, recurrent spontaneous
abortion, fetal growth retardation, early onset
preeclampsia and chorea gravidarum.
antibodies with phospholipid-protein specificity. LA may be
defined as an immunoglobulin, IgG or IgM or a mixture of
both, that interferes with one or more of the in-vitro
phospholipid (PL) dependent tests of coagulation. These
antibodies are not associated with a hemorrhagic diathesis,
but rather have been linked to thrombotic events. In
addition to thrombosis, other clinical complications have
been associated with the presence of LA. These include
strokes, nonbacterial thrombotic endocarditis, livedo
reticularis and a variety of obstetrical complications such
as intrauterine fetal death, recurrent spontaneous
abortion, fetal growth retardation, early onset
preeclampsia and chorea gravidarum.
